Plectin Therapeutics

Plectin Therapeutics is a biotechnology company dedicated to developing targeted therapies for high-unmet-need cancers, specifically focusing on pancreatic ductal adenocarcinoma. The company's proprietary platform targets Cell Surface Plectin (CSP), a protein that is translocated to the cell membrane in malignant cells but remains cytoplasmic in healthy tissue. This unique localization allows for the highly specific delivery of therapeutic agents, including monoclonal antibodies and drug conjugates, directly to tumor cells. By exploiting CSP as a tumor-specific handle, Plectin Therapeutics aims to create more effective and less toxic treatments for aggressive solid tumors. The company's pipeline includes both therapeutic and diagnostic applications designed to improve the management of recalcitrant cancers.